Baylor Pulmonary Hypertension Center, Baylor College of Medicine, USA
Dr. Zeenat Safdar received her MD from State University of New York, Health Science Center at Brooklyn, New York and completed her fellowship from Columbia University College of Physicians & Surgeons, St.Luke’s-Roosevelt Hospital Center, New York. She got NIH K23 award for her research in renin-angiotensin-aldosterone system in Pulmonary Hypertension.
Dr. Zeenat Safdar′s principle research area of interest is Pulmonary Arterial Hypertension (PAH), specifically patient-oriented clinical research and conduction of clinical trials. Her recent research has focused on the contribution of renin-angiotensin-aldosterone system in the pathophysiology of PAH. She is the principal and co-investigator of several ongoing clinical trials. These include COMPASS 2 [bosentan and sildenafil combination study], inhaled treprostinil, low dose sildenafil study, oral UT-15c (oral prostacyclin), COMPASS 3 [bosentan on cardiac remodeling], Athena-1 [ambrisentan combination with phosphodiesterase type-5 inhibitor], imatinib and tezosentan in PAH. She also provides expert care for patients with idiopathic pulmonary fibrosis (IPF) and interstitial lung diseases.